What the bad jobs report means for markets
HIGH POINT, NC – vTv Therapeutics Inc . (NASDAQ:VTVT), a pharmaceutical company with a market capitalization of approximately $59 million, announced the upcoming resignation of Executive Vice President and Chief Financial Officer Steven Tuch. Tuch has communicated his intention to step down effective March 21, 2025, as disclosed in a recent SEC filing.
The departure of Tuch, announced on Monday, is said to be amicable, with no disagreements between him and the company or its auditors reported. Tuch is set to remain with the company until the submission of the Annual Report on Form 10-K for the fiscal year ending December 31, 2024. The company has already initiated an external search to find Tuch’s successor.
vTv Therapeutics, which operates under the industrial classification of pharmaceutical preparations, is based in High Point, North Carolina, and is incorporated in Delaware. As part of the biotechnology sector, vTv Therapeutics focuses on the discovery and development of clinically differentiated drug candidates.
The company’s stock is traded on the Nasdaq Capital Market under the ticker symbol VTVT. The news of Tuch’s resignation comes amid a period of transition for the company, which has not provided further details on the reasons for his departure or any potential impact on the company’s operations.
This announcement is based on information from a press release statement and provides the latest update on the company’s executive team. Investors and stakeholders are awaiting further announcements regarding the appointment of a new CFO in the near future. The company is scheduled to report its next earnings on March 10, 2025, which may provide additional clarity on its financial direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.